Abstract
Background Prostate cancer (PCa) is the most common cancer and one of the leading causes of death worldwide. However, a significant proportion of PCa are low risk PCa which do not require an active treatment due to its low mortality rates. Thus, one major issue in PCa management is to accurately distinguish between indolent and clinically significant (cs) PCa to reduce overdiagnosis and overtreatment. In this study, we aim to validate the performance of diagnostic nomograms (DN) based on previously published urinary biomarkers for discriminating csPCa.
Patients and Methods Capillary electrophoresis/ mass spectrometry has been employed to validate a published biomarker model based on 19 urinary peptides specific for csPCa. Added value of the 19-biomarker model (19-BM) was assessed in diagnostic nomograms including prostate specific antigen (PSA), PSA density and the risk calculator from The European Randomized Study of Screening for Prostate Cancer (ERSPC). For this purpose, urine samples from 147 PCa patients (including 80 low, 44 intermediate and 17 high risk patients) were collected prior to prostate biopsy. The 19-BM score was calculated via a support vector machine-based software based on the pre-defined cut-off criterion of -0.07. DNs were subsequently developed to assess added value of integrative diagnostics.
Results Independent validation of the 19-BM resulted in 87% sensitivity and 65% specificity, with an AUC of 0.81, outperforming PSA (AUCPSA:0.64), PSA density (AUCPSAD: 0.64) and ERSPC-3/4 risk calculator (0.67). Integration of 19-BM with the other clinical variables into distinct DN, resulted in improved (AUC range: 0.82-0.88) but not significantly better performance compared to 19-BM alone.
Conclusions 19-BM alone or combined with clinical variables into DN, demonstrated value for detecting csPCa, and decreasing the number of biopsies.
Competing Interest Statement
Prof. Harald Mischak holds ownership interest in Mosaiques Diagnostics GmbH. Dr. Maria Frantzi is employed by Mosaiques Diagnostics GmbH. No potential conflicts of interest were disclosed by the other authors.
Funding Statement
This work was supported by the BioGuidePCa (E! 11023, Eurostars) funded by BMBF (Germany).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was performed as part of BioGuidePCa (E! 11023, Eurostars). Ethical approval was obtained by the Ethics Committee of Medical University Innsbruck (Innsbruck, Austria) in accordance with the Declaration of Helsinki and informed consent was obtained from all participants for the project.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations List
- AS
- Active Surveillance
- AUC
- Area Under ROC Curve
- CE
- Capillary Electrophoresis
- CI
- Confidence Intervals
- cs
- clinically significant
- DRE
- Digital Rectal Examination
- csPCa
- clinically significant PCa
- ERSPC
- The European Randomized Study of Screening for Prostate Cancer
- GS
- Gleason score
- MS
- Mass Spectrometry
- insPCa
- insignificant PCa
- PCa
- Prostate Cancer
- PSA
- Prostate Specific Antigen
- PSAD
- Prostate Specific Antigen Density
- ROC
- Receiver Operating Characteristics
- SVM
- Support Vector Machine.
